

# Radiopharmaceutical Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application

<https://marketpublishers.com/r/RE84F6B758C2EN.html>

Date: October 2025

Pages: 84

Price: US\$ 3,200.00 (Single User License)

ID: RE84F6B758C2EN

## Abstracts

### Radiopharmaceutical Market Summary

The radiopharmaceutical market, encompassing molecular imaging agents or diagnostic nuclear medicine tracers, represents a cornerstone of precision diagnostics in oncology, cardiology, and neurology, leveraging radioisotopes to illuminate physiological processes at the molecular level. These agents, typically comprising a short half-life radioisotope bound to a non-radioactive ligand or carrier such as peptides, antibodies, or carbohydrates, enable targeted accumulation in areas of interest like tumors or inflamed tissues. Upon injection, they emit detectable photons—either directly or via positron annihilation—that penetrate body tissues and are captured by specialized scanners, providing real-time insights into cellular function and metabolic activity far beyond anatomical imaging. This specificity facilitates early disease detection, treatment planning, and therapeutic monitoring, with formulations prepared on-site due to rapid decay, ensuring freshness and minimizing radiation exposure. The integration with advanced imaging modalities amplifies their utility in hybrid systems, supporting a paradigm shift toward theranostics, where diagnostic and therapeutic isotopes converge for personalized medicine. By 2025, the global radiopharmaceutical market is projected to reach USD 2.8–4.2 billion, fueled by escalating demand for non-invasive diagnostics amid rising chronic disease burdens. Forward projections indicate a compound annual growth rate (CAGR) of 4.5%–7.5% through 2030, propelled by innovations in isotope production and multimodal imaging adoption, though constrained by supply chain intricacies and regulatory demands.

### Regional Market Trends

North America commands a preeminent role in the radiopharmaceutical landscape, led by the United States, where sophisticated healthcare infrastructure and high cancer incidence rates drive voracious consumption. The U.S. thrives on streamlined FDA pathways for novel agents and generous reimbursement under Medicare Part B, fostering rapid clinical integration in academic medical centers and community hospitals alike. Growth is forecasted at a CAGR of 3.5%–5.5% through 2030, underpinned by surging PET utilization in oncology trials and the expansion of cyclotron networks for on-demand isotope generation, albeit tempered by reimbursement caps on high-cost tracers. Canada parallels this momentum through provincial health plans emphasizing cost-effective nuclear medicine, with Toronto and Vancouver emerging as hubs for cross-border collaborations, yet grappling with cyclotron access disparities in remote areas.

Europe exhibits steady maturation, with an estimated CAGR of 4.0%–6.0% through 2030, anchored by regulatory harmonization under the European Medicines Agency. Germany spearheads advancements as a nexus for radiochemistry research, bolstered by the German Cancer Aid initiatives that prioritize PET/MRI hybrids for precision oncology. France and the United Kingdom bolster the region's dynamism via national health services, where radiopharmaceuticals streamline workflows in high-throughput cardiology suites, though pricing pressures from the European Federation of Pharmaceutical Industries and Associations necessitate value demonstrations. Italy and Spain witness accelerating uptake in public oncology networks, driven by Mediterranean lifestyle-related disease surges, while Eastern European countries like Poland leverage EU funding for scanner installations, gradually bridging infrastructural gaps.

The Asia-Pacific arena surges with transformative potential, projecting a CAGR of 5.5%–8.0% through 2030, emblematic of its ascent as a diagnostic powerhouse. China propels this ascent through state-backed nuclear medicine programs under the 14th Five-Year Plan, emphasizing domestic cyclotron builds and PET/CT proliferation in tier-one cities like Shanghai. Japan and South Korea embody technological sophistication, with national insurance reforms subsidizing SPECT agents for dementia screening amid aging populations, complemented by robust R&D in antibody-based tracers. India ascends as a volume driver, with private diagnostic chains in Mumbai and Delhi adopting radiopharmaceuticals for affordable oncology imaging, notwithstanding rural-urban divides in scanner density. Australia contributes via stringent Therapeutic Goods Administration

approvals, while Southeast Asian nations such as Thailand harness medical tourism for premium PET services.

Latin America displays resilient expansion, with a CAGR of 4.5%–6.5% through 2030, centered on Brazil's unified health system (SUS) that channels investments into urban nuclear medicine facilities in Rio de Janeiro and São Paulo. Mexico follows with NAFTA-facilitated imports of advanced agents, empowering private clinics to address diabetes-related cardiac assessments via SPECT. Affordability barriers persist, yet pan-American health accords and local isotope production pilots in Argentina are democratizing access, particularly for therapeutic radiopharmaceuticals in palliative care.

The Middle East and Africa (MEA) emerge as high-growth frontiers, forecasted at a CAGR of 4.0%–6.0% through 2030, with Saudi Arabia and the United Arab Emirates at the vanguard via Vision 2030's healthcare digitization. Dubai's international medical hubs integrate PET/MRI for expatriate oncology, supported by sovereign wealth-funded cyclotron imports. South Africa advances through public-private ventures in Johannesburg, focusing on tuberculosis diagnostics with radiolabeled tracers, while sub-Saharan nations like Nigeria contend with logistics hurdles but benefit from WHO-backed training for SPECT deployment in infectious disease surveillance.

## Application Analysis

Radiopharmaceuticals are predominantly deployed in PET/CT, PET/MRI, and SPECT imaging, each modality harnessing the agents' molecular specificity to unravel disease dynamics with unparalleled resolution.

**PET/CT Applications:** This hybrid excels in oncology, fusing positron emission tomography's metabolic mapping with computed tomography's anatomical detail to stage cancers and monitor therapy responses, such as in prostate or breast malignancies. Trends spotlight theranostic extensions, where diagnostic PET guides lutetium-177 therapies, with procedural volumes ballooning due to AI-augmented quantification tools that enhance lesion detection sensitivity.

**PET/MRI Applications:** Offering superior soft-tissue contrast, PET/MRI radiopharmaceuticals shine in neuro-oncology and pediatrics, minimizing radiation while delineating brain tumors or epileptogenic foci via FDG or amyloid

tracers. Emerging developments include motion-corrected sequences for cardiac viability assessments, aligning with pediatric safety imperatives and driving adoption in specialized centers.

**SPECT Applications:** As a workhorse for cardiology and bone imaging, SPECT employs technetium-99m labeled agents for perfusion studies, detecting myocardial ischemia or metastases with cost-effective gamma detection. Evolutions emphasize multi-pinhole collimators for higher resolution, alongside hybrid SPECT/CT integrations that refine attenuation correction, sustaining relevance in resource-limited settings amid global cardiac disease epidemics.

## Company Profiles

**Lantheus:** A trailblazer in cardiovascular and oncology tracers, Lantheus' PYLARIFY® (piflufolastat F-18) dominates PSMA PET imaging for prostate cancer, bolstered by strategic expansions into theranostics. The company fortifies its North American footprint through manufacturing scale-ups, while venturing into APAC via distribution pacts.

**Curium Pharma:** Specializing in SPECT and PET agents, Curium's TechneScan® portfolio supports thyroid and renal diagnostics, with a focus on sustainable isotope production. Its European base drives R&D collaborations, extending reach into MEA through localized supply chains.

**GE HealthCare:** Integrating radiopharmaceuticals with its imaging ecosystem, GE's Cerianna® (fluoroestradiol F-18) advances breast cancer evaluation via PET/CT. The firm leverages global service networks for on-site formulation, targeting growth in Latin America's oncology surge.

**Siemens Healthineers:** Renowned for syngo.via software synergies, Siemens' portfolio includes gallium-68 generators for neuroendocrine tumors. In December 2024, it finalized the acquisition of Novartis' Advanced Accelerator Applications Molecular Imaging network, enhancing European PET distribution and manufacturing capabilities.

**Bracco:** Excelling in contrast-enhanced nuclear medicine, Bracco's NeoCart™ for cartilage repair diagnostics pairs with SPECT, emphasizing diagnostic accuracy. Its Italian heritage fuels innovations in multipurpose ligands, with expansions

into Asia-Pacific regulatory alignments.

**Telix Pharmaceuticals Limited:** Innovating in targeted radiopharmaceuticals, Telix's Illuccix® (kit for gallium-68 gozetotide) leads in renal cell imaging. The Australian-based entity pursues global Phase III trials, carving niches in urologic applications.

**Jubilant Life Sciences:** A key player in cyclotron-produced isotopes, Jubilant's FDG solutions power PET diagnostics in emerging markets. Through its radiopharma division, it invests in Indian manufacturing hubs to serve domestic and export demands.

**HTA Co. Ltd.:** Focusing on compact cyclotrons and automated synthesis modules, HTA enables decentralized production for short-lived tracers. The Korean firm targets APAC growth, partnering for PET/MRI integrations in high-density urban diagnostics.

## Industry Value Chain Analysis

The radiopharmaceutical value chain initiates with upstream isotope production, where cyclotrons or reactors generate short-lived nuclides like fluorine-18 or technetium-99m, demanding shielded facilities compliant with IAEA safeguards and GMP standards. This stage spans 24–48 hours per batch, incorporating precursor synthesis and quality assays for purity, often vertically integrated by majors like GE HealthCare to hedge supply volatilities.

Downstream, radiolabeling unites isotopes with ligands in hot cells, utilizing automated modules for sterility and yield optimization, followed by quality control via HPLC and dosimetry checks to affirm potency before distribution. Logistics pose critical bottlenecks, relying on lead-shielded transport with real-time tracking to preserve half-life integrity, typically within hours to end-users.

Commercialization unfolds through hospital-based pharmacies or commercial radiopharmacies, where on-site formulation tailors agents to scanner protocols, supported by just-in-time ordering systems. Marketing emphasizes clinical evidence from pivotal trials, showcased at SNMMI congresses, while payer negotiations highlight cost savings from reduced invasive biopsies. Post-market phases involve pharmacovigilance via FDA's MedWatch and iterative R&D for next-gen bifunctional

chelators, with sustainability efforts recycling lead shielding and minimizing waste in an environmentally conscious chain.

## Opportunities and Challenges

### Opportunities:

Escalating theranostics convergence, where diagnostic radiopharmaceuticals inform alpha-emitter therapies, expanding addressable markets in precision oncology and neuroendocrine treatments.

Decentralized production proliferation via compact cyclotrons, empowering emerging economies like India to curtail import dependencies and accelerate PET/SPECT access.

AI and machine learning integrations for image reconstruction, enhancing tracer uptake quantification and enabling predictive analytics in neurology applications.

Hybrid imaging modality synergies, such as PET/MRI advancements, to capture premium segments in pediatrics and cardiology with lower radiation profiles.

Global health initiatives targeting non-communicable diseases, fostering public-private partnerships for affordable agents in Latin America and MEA.

### Challenges:

Isotope supply chain fragilities, with molybdenum-99 shortages disrupting SPECT workflows and necessitating diversified reactor sources amid geopolitical strains.

Regulatory complexities for novel ligands, prolonging EMA/FDA approvals and escalating development timelines for targeted therapies.

High capital barriers for cyclotron installations, deterring adoption in rural or low-volume settings despite reimbursement incentives.

Radiation safety and waste management imperatives, imposing stringent training and disposal protocols that inflate operational costs.

Competitive pressures from biosimilars, eroding margins for incumbent tracers while demanding continuous innovation in binding affinities.

## Contents

### **CHAPTER 1 EXECUTIVE SUMMARY**

### **CHAPTER 2 ABBREVIATION AND ACRONYMS**

### **CHAPTER 3 PREFACE**

3.1 Research Scope

3.2 Research Sources

3.2.1 Data Sources

3.2.2 Assumptions

3.3 Research Method

Chapter Four Market Landscape

4.1 Market Overview

4.2 Classification/Types

4.3 Application/End Users

### **CHAPTER 5 MARKET TREND ANALYSIS**

5.1 Introduction

5.2 Drivers

5.3 Restraints

5.4 Opportunities

5.5 Threats

### **CHAPTER 6 INDUSTRY CHAIN ANALYSIS**

6.1 Upstream/Suppliers Analysis

6.2 Radiopharmaceutical Analysis

6.2.1 Technology Analysis

6.2.2 Cost Analysis

6.2.3 Market Channel Analysis

6.3 Downstream Buyers/End Users

### **CHAPTER 7 LATEST MARKET DYNAMICS**

7.1 Latest News

7.2 Merger and Acquisition

- 7.3 Planned/Future Project
- 7.4 Policy Dynamics

## **CHAPTER 8 HISTORICAL AND FORECAST RADIOPHARMACEUTICAL MARKET IN NORTH AMERICA (2020-2030)**

- 8.1 Radiopharmaceutical Market Size
- 8.2 Radiopharmaceutical Market by End Use
- 8.3 Competition by Players/Suppliers
- 8.4 Radiopharmaceutical Market Size by Type
- 8.5 Key Countries Analysis
  - 8.5.1 United States
  - 8.5.2 Canada
  - 8.5.3 Mexico

## **CHAPTER 9 HISTORICAL AND FORECAST RADIOPHARMACEUTICAL MARKET IN SOUTH AMERICA (2020-2030)**

- 9.1 Radiopharmaceutical Market Size
- 9.2 Radiopharmaceutical Market by End Use
- 9.3 Competition by Players/Suppliers
- 9.4 Radiopharmaceutical Market Size by Type
- 9.5 Key Countries Analysis

## **CHAPTER 10 HISTORICAL AND FORECAST RADIOPHARMACEUTICAL MARKET IN ASIA & PACIFIC (2020-2030)**

- 10.1 Radiopharmaceutical Market Size
- 10.2 Radiopharmaceutical Market by End Use
- 10.3 Competition by Players/Suppliers
- 10.4 Radiopharmaceutical Market Size by Type
- 10.5 Key Countries Analysis
  - 10.5.1 China
  - 10.5.2 India
  - 10.5.3 Japan
  - 10.5.4 South Korea
  - 10.5.5 Southeast Asia
  - 10.5.6 Australia & New Zealand

## **CHAPTER 11 HISTORICAL AND FORECAST RADIOPHARMACEUTICAL MARKET IN EUROPE (2020-2030)**

- 11.1 Radiopharmaceutical Market Size
- 11.2 Radiopharmaceutical Market by End Use
- 11.3 Competition by Players/Suppliers
- 11.4 Radiopharmaceutical Market Size by Type
- 11.5 Key Countries Analysis
  - 11.5.1 Germany
  - 11.5.2 France
  - 11.5.3 United Kingdom
  - 11.5.4 Italy
  - 11.5.5 Spain
  - 11.5.6 Belgium
  - 11.5.7 Netherlands
  - 11.5.8 Austria
  - 11.5.9 Poland
  - 11.5.10 Northern Europe

## **CHAPTER 12 HISTORICAL AND FORECAST RADIOPHARMACEUTICAL MARKET IN MEA (2020-2030)**

- 12.1 Radiopharmaceutical Market Size
- 12.2 Radiopharmaceutical Market by End Use
- 12.3 Competition by Players/Suppliers
- 12.4 Radiopharmaceutical Market Size by Type
- 12.5 Key Countries Analysis

## **CHAPTER 13 SUMMARY FOR GLOBAL RADIOPHARMACEUTICAL MARKET (2020-2025)**

- 13.1 Radiopharmaceutical Market Size
- 13.2 Radiopharmaceutical Market by End Use
- 13.3 Competition by Players/Suppliers
- 13.4 Radiopharmaceutical Market Size by Type

## **CHAPTER 14 GLOBAL RADIOPHARMACEUTICAL MARKET FORECAST (2025-2030)**

- 14.1 Radiopharmaceutical Market Size Forecast
- 14.2 Radiopharmaceutical Application Forecast
- 14.3 Competition by Players/Suppliers
- 14.4 Radiopharmaceutical Type Forecast

## **CHAPTER 15 ANALYSIS OF GLOBAL KEY VENDORS**

### 15.1 Lantheus

- 15.1.1 Company Profile
- 15.1.2 Main Business and Radiopharmaceutical Information
- 15.1.3 SWOT Analysis of Lantheus
- 15.1.4 Lantheus Radiopharmaceutical Revenue, Gross Margin and Market Share (2020-2025)

### 15.2 Curium Pharma

- 15.2.1 Company Profile
- 15.2.2 Main Business and Radiopharmaceutical Information
- 15.2.3 SWOT Analysis of Curium Pharma
- 15.2.4 Curium Pharma Radiopharmaceutical Revenue, Gross Margin and Market Share (2020-2025)

### 15.3 GE HealthCare

- 15.3.1 Company Profile
- 15.3.2 Main Business and Radiopharmaceutical Information
- 15.3.3 SWOT Analysis of GE HealthCare
- 15.3.4 GE HealthCare Radiopharmaceutical Revenue, Gross Margin and Market Share (2020-2025)

### 15.4 Siemens Healthineers

- 15.4.1 Company Profile
- 15.4.2 Main Business and Radiopharmaceutical Information
- 15.4.3 SWOT Analysis of Siemens Healthineers
- 15.4.4 Siemens Healthineers Radiopharmaceutical Revenue, Gross Margin and Market Share (2020-2025)

### 15.5 Bracco

- 15.5.1 Company Profile
- 15.5.2 Main Business and Radiopharmaceutical Information
- 15.5.3 SWOT Analysis of Bracco
- 15.5.4 Bracco Radiopharmaceutical Revenue, Gross Margin and Market Share (2020-2025)

### 15.6 Telix Pharmaceuticals Limited

- 15.6.1 Company Profile

- 15.6.2 Main Business and Radiopharmaceutical Information
  - 15.6.3 SWOT Analysis of Telix Pharmaceuticals Limited
  - 15.6.4 Telix Pharmaceuticals Limited Radiopharmaceutical Revenue, Gross Margin and Market Share (2020-2025)
  - 15.7 Jubilant Life Sciences
    - 15.7.1 Company Profile
    - 15.7.2 Main Business and Radiopharmaceutical Information
    - 15.7.3 SWOT Analysis of Jubilant Life Sciences
    - 15.7.4 Jubilant Life Sciences Radiopharmaceutical Revenue, Gross Margin and Market Share (2020-2025)
  - 15.8 HTA Co. Ltd.
    - 15.8.1 Company Profile
    - 15.8.2 Main Business and Radiopharmaceutical Information
    - 15.8.3 SWOT Analysis of HTA Co. Ltd.
    - 15.8.4 HTA Co. Ltd. Radiopharmaceutical Revenue, Gross Margin and Market Share (2020-2025)
- Please ask for sample pages for full companies list

## Tables & Figures

### TABLES AND FIGURES

- Table Abbreviation and Acronyms
- Table Research Scope of Radiopharmaceutical Report
- Table Data Sources of Radiopharmaceutical Report
- Table Major Assumptions of Radiopharmaceutical Report
- Figure Market Size Estimated Method
- Figure Major Forecasting Factors
- Figure Radiopharmaceutical Picture
- Table Radiopharmaceutical Classification
- Table Radiopharmaceutical Applications
- Table Drivers of Radiopharmaceutical Market
- Table Restraints of Radiopharmaceutical Market
- Table Opportunities of Radiopharmaceutical Market
- Table Threats of Radiopharmaceutical Market
- Table COVID-19 Impact for Radiopharmaceutical Market
- Table Raw Materials Suppliers
- Table Different Production Methods of Radiopharmaceutical
- Table Cost Structure Analysis of Radiopharmaceutical
- Table Key End Users
- Table Latest News of Radiopharmaceutical Market
- Table Merger and Acquisition
- Table Planned/Future Project of Radiopharmaceutical Market
- Table Policy of Radiopharmaceutical Market
- Table 2020-2030 North America Radiopharmaceutical Market Size
- Figure 2020-2030 North America Radiopharmaceutical Market Size and CAGR
- Table 2020-2030 North America Radiopharmaceutical Market Size by Application
- Table 2020-2025 North America Radiopharmaceutical Key Players Revenue
- Table 2020-2025 North America Radiopharmaceutical Key Players Market Share
- Table 2020-2030 North America Radiopharmaceutical Market Size by Type
- Table 2020-2030 United States Radiopharmaceutical Market Size
- Table 2020-2030 Canada Radiopharmaceutical Market Size
- Table 2020-2030 Mexico Radiopharmaceutical Market Size
- Table 2020-2030 South America Radiopharmaceutical Market Size
- Figure 2020-2030 South America Radiopharmaceutical Market Size and CAGR
- Table 2020-2030 South America Radiopharmaceutical Market Size by Application
- Table 2020-2025 South America Radiopharmaceutical Key Players Revenue

Table 2020-2025 South America Radiopharmaceutical Key Players Market Share  
Table 2020-2030 South America Radiopharmaceutical Market Size by Type  
Table 2020-2030 Asia & Pacific Radiopharmaceutical Market Size  
Figure 2020-2030 Asia & Pacific Radiopharmaceutical Market Size and CAGR  
Table 2020-2030 Asia & Pacific Radiopharmaceutical Market Size by Application  
Table 2020-2025 Asia & Pacific Radiopharmaceutical Key Players Revenue  
Table 2020-2025 Asia & Pacific Radiopharmaceutical Key Players Market Share  
Table 2020-2030 Asia & Pacific Radiopharmaceutical Market Size by Type  
Table 2020-2030 China Radiopharmaceutical Market Size  
Table 2020-2030 India Radiopharmaceutical Market Size  
Table 2020-2030 Japan Radiopharmaceutical Market Size  
Table 2020-2030 South Korea Radiopharmaceutical Market Size  
Table 2020-2030 Southeast Asia Radiopharmaceutical Market Size  
Table 2020-2030 Australia & New Zealand Radiopharmaceutical Market Size  
Table 2020-2030 Europe Radiopharmaceutical Market Size  
Figure 2020-2030 Europe Radiopharmaceutical Market Size and CAGR  
Table 2020-2030 Europe Radiopharmaceutical Market Size by Application  
Table 2020-2025 Europe Radiopharmaceutical Key Players Revenue  
Table 2020-2025 Europe Radiopharmaceutical Key Players Market Share  
Table 2020-2030 Europe Radiopharmaceutical Market Size by Type  
Table 2020-2030 Germany Radiopharmaceutical Market Size  
Table 2020-2030 France Radiopharmaceutical Market Size  
Table 2020-2030 United Kingdom Radiopharmaceutical Market Size  
Table 2020-2030 Italy Radiopharmaceutical Market Size  
Table 2020-2030 Spain Radiopharmaceutical Market Size  
Table 2020-2030 Belgium Radiopharmaceutical Market Size  
Table 2020-2030 Netherlands Radiopharmaceutical Market Size  
Table 2020-2030 Austria Radiopharmaceutical Market Size  
Table 2020-2030 Poland Radiopharmaceutical Market Size  
Table 2020-2030 Northern Europe Radiopharmaceutical Market Size  
Table 2020-2030 MEA Radiopharmaceutical Market Size  
Figure 2020-2030 MEA Radiopharmaceutical Market Size and CAGR  
Table 2020-2030 MEA Radiopharmaceutical Market Size by Application  
Table 2020-2025 MEA Radiopharmaceutical Key Players Revenue  
Table 2020-2025 MEA Radiopharmaceutical Key Players Market Share  
Table 2020-2030 MEA Radiopharmaceutical Market Size by Type  
Table 2020-2025 Global Radiopharmaceutical Market Size by Region  
Table 2020-2025 Global Radiopharmaceutical Market Size Share by Region  
Table 2020-2025 Global Radiopharmaceutical Market Size by Application

Table 2020-2025 Global Radiopharmaceutical Market Share by Application  
Table 2020-2025 Global Radiopharmaceutical Key Vendors Revenue  
Figure 2020-2025 Global Radiopharmaceutical Market Size and Growth Rate  
Table 2020-2025 Global Radiopharmaceutical Key Vendors Market Share  
Table 2020-2025 Global Radiopharmaceutical Market Size by Type  
Table 2020-2025 Global Radiopharmaceutical Market Share by Type  
Table 2025-2030 Global Radiopharmaceutical Market Size by Region  
Table 2025-2030 Global Radiopharmaceutical Market Size Share by Region  
Table 2025-2030 Global Radiopharmaceutical Market Size by Application  
Table 2025-2030 Global Radiopharmaceutical Market Share by Application  
Table 2025-2030 Global Radiopharmaceutical Key Vendors Revenue  
Figure 2025-2030 Global Radiopharmaceutical Market Size and Growth Rate  
Table 2025-2030 Global Radiopharmaceutical Key Vendors Market Share  
Table 2025-2030 Global Radiopharmaceutical Market Size by Type  
Table 2025-2030 Radiopharmaceutical Global Market Share by Type  
Table Lantheus Information  
Table SWOT Analysis of Lantheus  
Table 2020-2025 Lantheus Radiopharmaceutical Revenue Gross Profit Margin  
Figure 2020-2025 Lantheus Radiopharmaceutical Revenue and Growth Rate  
Figure 2020-2025 Lantheus Radiopharmaceutical Market Share  
Table Curium Pharma Information  
Table SWOT Analysis of Curium Pharma  
Table 2020-2025 Curium Pharma Radiopharmaceutical Revenue Gross Profit Margin  
Figure 2020-2025 Curium Pharma Radiopharmaceutical Revenue and Growth Rate  
Figure 2020-2025 Curium Pharma Radiopharmaceutical Market Share  
Table GE HealthCare Information  
Table SWOT Analysis of GE HealthCare  
Table 2020-2025 GE HealthCare Radiopharmaceutical Revenue Gross Profit Margin  
Figure 2020-2025 GE HealthCare Radiopharmaceutical Revenue and Growth Rate  
Figure 2020-2025 GE HealthCare Radiopharmaceutical Market Share  
Table Siemens Healthineers Information  
Table SWOT Analysis of Siemens Healthineers  
Table 2020-2025 Siemens Healthineers Radiopharmaceutical Revenue Gross Profit Margin  
Figure 2020-2025 Siemens Healthineers Radiopharmaceutical Revenue and Growth Rate  
Figure 2020-2025 Siemens Healthineers Radiopharmaceutical Market Share  
Table Bracco Information  
Table SWOT Analysis of Bracco

Table 2020-2025 Bracco Radiopharmaceutical Revenue Gross Profit Margin  
Figure 2020-2025 Bracco Radiopharmaceutical Revenue and Growth Rate  
Figure 2020-2025 Bracco Radiopharmaceutical Market Share  
Table Telix Pharmaceuticals Limited Information  
Table SWOT Analysis of Telix Pharmaceuticals Limited  
Table 2020-2025 Telix Pharmaceuticals Limited Radiopharmaceutical Revenue Gross Profit Margin  
Figure 2020-2025 Telix Pharmaceuticals Limited Radiopharmaceutical Revenue and Growth Rate  
Figure 2020-2025 Telix Pharmaceuticals Limited Radiopharmaceutical Market Share  
Table Jubilant Life Sciences Information  
Table SWOT Analysis of Jubilant Life Sciences  
Table 2020-2025 Jubilant Life Sciences Radiopharmaceutical Revenue Gross Profit Margin  
Figure 2020-2025 Jubilant Life Sciences Radiopharmaceutical Revenue and Growth Rate  
Figure 2020-2025 Jubilant Life Sciences Radiopharmaceutical Market Share  
Table HTA Co. Ltd. Information  
Table SWOT Analysis of HTA Co. Ltd.  
Table 2020-2025 HTA Co. Ltd. Radiopharmaceutical Revenue Gross Profit Margin  
Figure 2020-2025 HTA Co. Ltd. Radiopharmaceutical Revenue and Growth Rate  
Figure 2020-2025 HTA Co. Ltd. Radiopharmaceutical Market Share

.....

## I would like to order

Product name: Radiopharmaceutical Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application

Product link: <https://marketpublishers.com/r/RE84F6B758C2EN.html>

Price: US\$ 3,200.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/RE84F6B758C2EN.html>